stockrowAC Immune
ACIUAC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024.
- Revenue
- +152.3%
- EPS
- +36.0%
- Free cash flow
- +4.66%
Quarter to September 2026, against a year earlier
Follow ACIU
Alert me
AC Immune (ACIU) EV/Sales
As of 6 November 2026, AC Immune (ACIU) trades at a EV/Sales of 9.1×. Over the past ten years it has ranged from −0.3× (April 2025) to 117× (December 2017); the current reading is higher than 44% of that period. That is in line with the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 48.3× | 1,695.76% |
| FY2024 | 2.7× | (93.93%) |
| FY2023 | 44.4× | 385.70% |
| FY2022 | 9.1× | 12.90% |
| FY2020 | 8.1× | 188.24% |
| FY2019 | 2.8× | (94.76%) |
| FY2018 | 53.6× | 73.48% |
| FY2017 | 30.9× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 12.8× | (67.18%) |
| Mar 2026 | 38.9× | (19.44%) |
| Dec 2025 | 48.3× | 42.44% |
| Sep 2025 | 33.9× | 2,024.65% |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | 0.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.1× |
| ACIU AC Immune | 9.1× |
| FATE Fate Therapeutics, Inc. compare | 14.0× |
| KRRO Korro Bio, Inc. compare | 25.5× |
| SLGL Sol-Gel Technologies Ltd. compare | 121× |
| IMRX Immuneering Corporation compare | 293× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)